Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics is poised for a positive outlook due to its clinical-stage product candidate, lorundrostat, which has demonstrated a significant placebo-adjusted blood pressure benefit of over 10 mmHg in patients with uncontrolled and resistant hypertension. The differentiated profile of lorundrostat, particularly in the context of Phase 3 clinical data and comprehensive 24-hour ambulatory blood pressure monitoring, underscores its potential to meet an unmet medical need in this patient population. Furthermore, the company is on track for near-term FDA feedback and an anticipated New Drug Application (NDA) submission, positioning Mineralys Therapeutics favorably within the biopharmaceutical landscape.

Bears say

Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from uncertainties regarding the commercial viability of its developmental candidate, lorundrostat. Key risks include the potential failure to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies, as well as challenges in securing the necessary capital to fund ongoing operations. Additionally, concerns related to the continued development and commercialization of lorundrostat further exacerbate the investment thesis, particularly in light of potential patient safety issues, such as hyperkalemia, which could influence market acceptance and regulatory approval.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.